{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:53:49Z","timestamp":1792122829355,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Israel Institute for Biological Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Novichoks are the latest known and most toxic class of organophosphorus chemical warfare agents (OP CWAs) to have been developed. Among the documented Novichoks, A-232 is the most toxic and most potent inhibitor of AChE, as well as the most resistant to reactivation by oximes, and thus likely the most challenging to treat. Here we characterize the intoxication following dermal exposure to the Novichok A-232 in swine, and describe a novel countermeasure against it. Our results demonstrate that percutaneous poisoning by a lethal dose of A-232 (2 mg\/kg) is characterized by slow appearance and exacerbation of intoxication signs. We further show that conventional antidotal treatment against such poisoning, administered upon appearance of intoxication signs, provides only temporary relief after which intoxication signs reoccur, and that further repeated such treatment is not sufficient to enable survival. The above likely stem from formation of a dermal depot of A-232 from which the agent slowly penetrates into the bloodstream, coupled with its resistance to reactivation by oximes. Accordingly, we developed the AHAK lotion (potassium acetohydroxamate in DMSO\/H\n                    <jats:sub>2<\/jats:sub>\n                    O, derived from the FDA approved medication acetohydroxamic acid (AHA)), intended to act as a \u2018catch-up therapy\u2019 enabling both skin surface and intradermal decomposition of persistent low-volatility OP CWAs. We demonstrate that combining conventional antidotal treatment with dermal application of AHAK following percutaneous poisoning by a lethal dose of A-232, leads to survival of all animals. Additionally, using a low dose (0.33\u20130.41 mg\/kg) of A-232, we show that AHAK is expected to exert a beneficial effect also following late application. Hence, the results of the current study, coupled with our previous results regarding the contribution of AHAK to countering percutaneous intoxication by VX and the safety of prolonged whole-body application of AHAK, delineate the aptness of AHAK to serve as a generic medical countermeasure against percutaneous intoxication by persistent low-volatility OP CWAs, of both the V and Novichok families.\n                  <\/jats:p>","DOI":"10.1007\/s00204-026-04355-6","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:48:35Z","timestamp":1776714515000},"page":"2899-2917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AHAK: a new effective medical countermeasure against percutaneous intoxication by Novichok chemical warfare agents"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-5857","authenticated-orcid":false,"given":"Uri","family":"Nili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Nahum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Smolkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-6994","authenticated-orcid":false,"given":"Nissan","family":"Ashkenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8962-6686","authenticated-orcid":false,"given":"Eugenia","family":"Bloch-Shilderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"4355_CR1","unstructured":"Acetohydroxamic acid. PubChem. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/1990. Accessed 22 May 2023"},{"key":"4355_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tox.2006.04.030","volume":"224","author":"N Aurbek","year":"2006","unstructured":"Aurbek N, Thiermann H, Szinicz L, Eyer P, Worek F (2006) Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase. Toxicology 224:91\u201399. https:\/\/doi.org\/10.1016\/j.tox.2006.04.030","journal-title":"Toxicology"},{"key":"4355_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1523-1747.ep12538909","volume":"58","author":"MJ Bartek","year":"1972","unstructured":"Bartek MJ, LaBudde JA, Maibach HI (1972) Skin permeability in vivo: comparison in rat, rabbit, pig and man. J Invest Dermatol 58:114\u2013123","journal-title":"J Invest Dermatol"},{"key":"4355_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00204-017-2108-5","volume":"92","author":"E Bloch-Shilderman","year":"2018","unstructured":"Bloch-Shilderman E, Rabinovitz I, Egoz I, Yacov G, Allon N, Nili U (2018) Determining a threshold sub-acute dose leading to minimal physiological alterations following prolonged exposure to the nerve agent VX in rats. Arch Toxicol 92:873\u2013892. https:\/\/doi.org\/10.1007\/s00204-017-2108-5","journal-title":"Arch Toxicol"},{"key":"4355_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00204-019-02401-0","volume":"93","author":"E Bloch-Shilderman","year":"2019","unstructured":"Bloch-Shilderman E, Yacov G, Cohen L, Egoz I, Gutman H, Gez R, Rabinovitz I, Nili U (2019) Repetitive antidotal treatment is crucial in eliminating eye pathology, respiratory toxicity and death following whole-body VX vapor exposure in freely moving rats. Arch Toxicol 93:1365\u20131384. https:\/\/doi.org\/10.1007\/s00204-019-02401-0","journal-title":"Arch Toxicol"},{"key":"4355_CR6","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00204-023-03574-5","volume":"97","author":"E Bloch-Shilderman","year":"2023","unstructured":"Bloch-Shilderman E, Nili U, Nahum V, Smolkin B, Ashkenazi N (2023) \u201cCatch-up\u201d therapy: combining antidotal treatment with dermal application of AHA following percutaneous VX poisoning in the domestic swine. Arch Toxicol 97:2771\u20132783. https:\/\/doi.org\/10.1007\/s00204-023-03574-5","journal-title":"Arch Toxicol"},{"key":"4355_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usad464","author":"TL Blom","year":"2023","unstructured":"Blom TL, Winglelaar TT (2023) Current perspectives on the management of patients poisoned with Novichok: a scoping review. Mil Med. https:\/\/doi.org\/10.1093\/milmed\/usad464","journal-title":"Mil Med"},{"key":"4355_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00204-022-03273-7","volume":"96","author":"HM Bolt","year":"2022","unstructured":"Bolt HM, Hengstler JG (2022) Recent research on Novichok. Arch Toxicol 96:1137\u20131140. https:\/\/doi.org\/10.1007\/s00204-022-03273-7","journal-title":"Arch Toxicol"},{"key":"4355_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/15569527.2010.515280","volume":"30","author":"EH Braue Jr","year":"2011","unstructured":"Braue EH Jr, Smith KH, Doxzon BF, Lumpkin HL, Clarkson ED (2011) Efficacy studies of reactive skin decontamination lotion, M291 skin decontamination Kit, 0.5% bleach, 1% soapy water, and skin exposure reduction paste against chemical warfare agents, part 1: guinea pigs challenged with VX. Cutan Ocul Toxicol 30:15\u201328. https:\/\/doi.org\/10.3109\/15569527.2010.515280","journal-title":"Cutan Ocul Toxicol"},{"key":"4355_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1191\/0960327103ht359oa","volume":"22","author":"RP Chilcott","year":"2003","unstructured":"Chilcott RP, Dalton CH, Hill I, Davidson CM, Blohm KL, Hamilton MG (2003) Clinical manifestations of VX poisoning following percutaneous exposure in the domestic white pig. Hum Exp Toxicol 22:255\u2013261. https:\/\/doi.org\/10.1191\/0960327103ht359oa","journal-title":"Hum Exp Toxicol"},{"key":"4355_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1191\/0960327105ht537oa","volume":"24","author":"RP Chilcott","year":"2005","unstructured":"Chilcott RP, Dalton CH, Hill I, Davison CM, Blohm KL, Clarkson ED, Hamilton MG (2005a) In vivo skin absorption and distribution of the nerve agent VX (O\u2013ethyl\u2013S\u2013[2(diisopropylamino)ethyl] methylphosphonothioate) in the domestic white pig. Hum Exp Toxicol 24:347\u2013352. https:\/\/doi.org\/10.1191\/0960327105ht537oa","journal-title":"Hum Exp Toxicol"},{"key":"4355_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1742-7843.2005.pto_97106.x","volume":"97","author":"RP Chilcott","year":"2005","unstructured":"Chilcott RP, Dalton CH, Hill I, Davison CM, Blohm KL, Clarkson ED, Hamilton MG (2005b) Evaluation of a barrier cream against the chemical warfare agent VX using the domestic white pig. Basic Clin Pharmacol Toxicol 97:35\u201338. https:\/\/doi.org\/10.1111\/j.1742-7843.2005.pto_97106.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4355_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1523-1747","volume":"68","author":"FN Craig","year":"1977","unstructured":"Craig FN, Cummings EG, Sim VM (1977) Environmental temperature and the percutaneous absorption of a cholinesterase inhibitor, VX. J Invest Dermatol 68:357\u2013361. https:\/\/doi.org\/10.1111\/1523-1747","journal-title":"J Invest Dermatol"},{"key":"4355_CR14","doi-asserted-by":"publisher","first-page":"140016","DOI":"10.1016\/j.jPMID:41037904","volume":"498","author":"I Columbus","year":"2025","unstructured":"Columbus I, Fridkin G, Yehezkel L, Pevzner A, Levi N, Sod-Moriah G, Zafrani Y, Smolkin B, Chen RJ (2025) Fate and decontamination of Novichok agent A232 on environmental and urban matrices. J Hazard Mater 498:140016. https:\/\/doi.org\/10.1016\/j.jPMID:41037904","journal-title":"J Hazard Mater"},{"key":"4355_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1684\/ejd.2013.2060","volume":"23","author":"S Debeer","year":"2013","unstructured":"Debeer S, Le Luduec JB, Kaiserlian D, Laurent P, Nicolas JF, Dubois B, Kanitakis J (2013) Comparative histology and immunohistochemistry of porcine versus human skin. Eur J Dermatol 23:456\u2013466. https:\/\/doi.org\/10.1684\/ejd.2013.2060","journal-title":"Eur J Dermatol"},{"key":"4355_CR16","doi-asserted-by":"publisher","first-page":"9222","DOI":"10.1021\/acsami.1c24295","volume":"14","author":"MC de Koning","year":"2022","unstructured":"de Koning MC, Vieira Soares C, van Grol M, Bross RPT, Maurin G (2022) Effective degradation of Novichok nerve agents by the zirconium metal-organic framework MOF-808. ACS Appl Mater Interfaces 14:9222\u20139230. https:\/\/doi.org\/10.1021\/acsami.1c24295","journal-title":"ACS Appl Mater Interfaces"},{"key":"4355_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tox.2006.09.013","volume":"233","author":"F Dorandeu","year":"2007","unstructured":"Dorandeu F, Mikler JR, Thiermann H, Tenn C, Davidson C, Sawyer TW, Lallement G, Worek F (2007) Swine models in the design of more effective medical countermeasures against organophosphorus poisoning. Toxicology 233:128\u2013144. https:\/\/doi.org\/10.1016\/j.tox.2006.09.013","journal-title":"Toxicology"},{"key":"4355_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00204-022-03408-w","volume":"97","author":"F F\u00e9my","year":"2023","unstructured":"F\u00e9my F, Meesemaecker G, Belverge N, Courageux C, Nervo A, Goulay R, Reymond C, Chantegreil F, Madi M, Nachon F, Taudon N, Jafr\u00e9 N (2023) Toxicokinetics of plasmatic VX in a swine model: comparison of a simple enzymatic titration method with a mass spectrometry method. Arch Toxicol 97:421\u2013428. https:\/\/doi.org\/10.1007\/s00204-022-03408-w","journal-title":"Arch Toxicol"},{"key":"4355_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1172\/JCI103615","volume":"37","author":"D Grob","year":"1958","unstructured":"Grob D, Harvey JC (1958) Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J Clin Invest 37:350\u2013368. https:\/\/doi.org\/10.1172\/JCI103615","journal-title":"J Clin Invest"},{"key":"4355_CR20","doi-asserted-by":"publisher","first-page":"856","DOI":"10.7205\/milmed.169.11.856","volume":"169","author":"MG Hamilton","year":"2004","unstructured":"Hamilton MG, Hill I, Conley J, Sawyer TW, Caneva DC, Lundy PM (2004) Clinical aspects of percutaneous poisoning by the chemical warfare agent VX: effects of application site and decontamination. Mil Med 169:856\u2013862. https:\/\/doi.org\/10.7205\/milmed.169.11.856","journal-title":"Mil Med"},{"key":"4355_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1006\/rtph.2002.1547","volume":"35","author":"HM Hartmann","year":"2002","unstructured":"Hartmann HM (2002) Evaluation of risk assessment guideline levels for the chemical warfare agents mustard, GB, and VX. Regul Toxicol Pharmacol 35:347\u2013356. https:\/\/doi.org\/10.1006\/rtph.2002.1547","journal-title":"Regul Toxicol Pharmacol"},{"key":"4355_CR22","doi-asserted-by":"publisher","first-page":"e03153","DOI":"10.1016\/j.heliyon.2019.e03153","volume":"6","author":"SP Harvey","year":"2020","unstructured":"Harvey SP, McMahon LR, Berg FJ (2020) Hydrolysis and enzymatic degradation of Novichok nerve agents. Heliyon 6:e03153. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e03153","journal-title":"Heliyon"},{"key":"4355_CR23","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00204-024-03689-3","volume":"98","author":"M Hrabinova","year":"2024","unstructured":"Hrabinova M, Pejchal J, Hepnarova V, Muckova L, Junova L, Opravil J, Zdarova Karasova J, Rozsypal T, Dlabkova A, Rehulkova H, Kucera T, Vecera Z, Caisberger F, Schmidt M, Soukup O, Jun D (2024) A-series agent A-234: initial in vitro and in vivo characterization. Arch Toxicol 98:1135\u20131149. https:\/\/doi.org\/10.1007\/s00204-024-03689-3","journal-title":"Arch Toxicol"},{"key":"4355_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2478\/aiht-2020-71-3459","volume":"71","author":"NM Hrvat","year":"2020","unstructured":"Hrvat NM, Kovarik Z (2020) Counteracting poisoning with chemical warfare nerve agents. Arh Hig Rada Toksikol 71:266\u2013284. https:\/\/doi.org\/10.2478\/aiht-2020-71-3459","journal-title":"Arh Hig Rada Toksikol"},{"key":"4355_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bja.2019.04.061","volume":"123","author":"EJ Hulse","year":"2019","unstructured":"Hulse EJ, Haslam JD, Emmett SR, Woolley T (2019) Organophosphorus nerve agent poisoning: managing the poisoned patient. Br J Anaesth 123:457\u2013463. https:\/\/doi.org\/10.1016\/j.bja.2019.04.061","journal-title":"Br J Anaesth"},{"key":"4355_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0003-2697(75)90423-6","volume":"64","author":"CD Johnson","year":"1975","unstructured":"Johnson CD, Russell RL (1975) A rapid simple radiometric assay for cholinesterase suitable for multiple determinations. Anal Biochem 64:229\u2013238. https:\/\/doi.org\/10.1016\/0003-2697(75)90423-6","journal-title":"Anal Biochem"},{"key":"4355_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cbi.2010.06.010","volume":"188","author":"MJA Joosen","year":"2010","unstructured":"Joosen MJA, van der Schans MJ, van Helden HPM (2010) Percutaneous exposure to the nerve agent VX: efficacy of combined atropine, obidoxime and diazepam treatment. Chem Biol Interact 188:255\u2013263. https:\/\/doi.org\/10.1016\/j.cbi.2010.06.010","journal-title":"Chem Biol Interact"},{"key":"4355_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cbi.2012.10.002","volume":"203","author":"MJA Joosen","year":"2013","unstructured":"Joosen MJA, van der Schans MJ, Kuijpers WC, van Helden HPM, Noort D (2013) Timing of decontamination and treatment in case of percutaneous VX poisoning: a mini review. Chem Biol Interact 203:149\u2013153. https:\/\/doi.org\/10.1016\/j.cbi.2012.10.002","journal-title":"Chem Biol Interact"},{"key":"4355_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cbi.2016.02.001","volume":"267","author":"MJ Joosen","year":"2017","unstructured":"Joosen MJ, van den Berg RM, de Jong AL, van der Schans MJ, Noort D, Langenberg JP (2017) The impact of skin decontamination on the time window for effective treatment of percutaneous VX exposure. Chem Biol Interact 267:48\u201356. https:\/\/doi.org\/10.1016\/j.cbi.2016.02.001","journal-title":"Chem Biol Interact"},{"key":"4355_CR30","doi-asserted-by":"publisher","first-page":"111762","DOI":"10.1016\/j.cbi.2025.111762","volume":"421","author":"Z Kovarik","year":"2025","unstructured":"Kovarik Z, Koli\u0107 D, \u010cade\u017e T, \u0160inko G, Tuksar P, Zorbaz T, Curty C, Hrvat NM (2025) Outlining the A-series of organophosphorus compounds: cholinesterase inhibition, reactivation, cytotoxicity, and acute toxicity in mice. Chem Biol Interact 421:111762. https:\/\/doi.org\/10.1016\/j.cbi.2025.111762","journal-title":"Chem Biol Interact"},{"key":"4355_CR31","unstructured":"Lithostat official label. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=6660b616-a82d-9109-19ce-2bdf9747acea&type=display Accessed 22 May 2023"},{"key":"4355_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/9780470060032.ch8","volume-title":"Chemical warfare agents: toxicology and treatment","author":"TC Marrs","year":"2007","unstructured":"Marrs TC (2007) Toxicology of organophosphate nerve agents. In: Marrs TC, Maynard RL, Sidell F (eds) Chemical warfare agents: toxicology and treatment, 2nd edn. Wiley, Chichester, pp 191\u2013222. https:\/\/doi.org\/10.1002\/9780470060032.ch8","edition":"2nd edn"},{"key":"4355_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/occmed\/50.5.343","volume":"50","author":"HJ Mason","year":"2000","unstructured":"Mason HJ (2000) The recovery of plasma cholinesterase and erythrocyte acetylcholinesterase activity in workers after over-exposure to dichlorvos. Occup Med 50:343\u2013347. https:\/\/doi.org\/10.1093\/occmed\/50.5.343","journal-title":"Occup Med"},{"key":"4355_CR34","unstructured":"Mirzayanov VS (2008) State secrets: an insider\u2019s chronicle of the Russian chemical weapons program, Outskirts Press Inc."},{"key":"4355_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1289\/ehp.9410218","volume":"102","author":"NB Munro","year":"1994","unstructured":"Munro NB, Ambrose KR, Watson AP (1994) Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ Health Perspect 102:18\u201338. https:\/\/doi.org\/10.1289\/ehp.9410218","journal-title":"Environ Health Perspect"},{"key":"4355_CR36","doi-asserted-by":"publisher","first-page":"120689","DOI":"10.1016\/j.ijpharm.2021.120689","volume":"603","author":"V Nahum","year":"2021","unstructured":"Nahum V, Nili U, Bloch-Shilderman E, Smolkin B, Ashkenazi N (2021) Towards catch-up therapy: evaluation of nucleophilic active pharmaceutical ingredients for the treatment of percutaneous VX poisoning, in-vial and in-vitro studies. Int J Pharm 603:120689. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120689","journal-title":"Int J Pharm"},{"key":"4355_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jat.2730","volume":"33","author":"RS Naik","year":"2012","unstructured":"Naik RS, Liu W, Saxena A (2012) Development and validation of a simple assay for the determination of cholinesterase activity in whole blood of laboratory animals. J Appl Toxicol 33:290\u2013300. https:\/\/doi.org\/10.1002\/jat.2730","journal-title":"J Appl Toxicol"},{"key":"4355_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703","journal-title":"J Basic Clin Pharm"},{"issue":"8","key":"4355_CR39","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/acs.bioconjchem.5b00305","volume":"26","author":"T Noy-Porat","year":"2015","unstructured":"Noy-Porat T, Cohen O, Ehrlich S, Epstein E, Alcalay R, Mazor O (2015) Acetylcholinesterase-Fc fusion protein (AChE-Fc): a novel potential organophosphate bioscavenger with extended plasma half-life. Bioconjug Chem 26(8):1753\u20131758. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00305","journal-title":"Bioconjug Chem"},{"key":"4355_CR40","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S0140-6736(95)92306-3","volume":"346","author":"H Nozaki","year":"1995","unstructured":"Nozaki H, Aikawa N, Fujishima S, Suzuki M, Shinozawa Y, Hori S, Nogawa S (1995) A case of VX poisoning and the difference from Sarin. Lancet 346:698\u2013699. https:\/\/doi.org\/10.1016\/S0140-6736(95)92306-3","journal-title":"Lancet"},{"key":"4355_CR41","unstructured":"OPCW. Technical Assistance provided by OPCW related to toxic chemical incidents in Salisbury and Amesbury. https:\/\/www.opcw.org\/media-centre\/featured-topics\/incident-salisbury Accessed 6 Mar 2025"},{"issue":"2176","key":"4355_CR42","doi-asserted-by":"publisher","first-page":"20140891","DOI":"10.1098\/rspa.2014.0891","volume":"471","author":"H Rice","year":"2015","unstructured":"Rice H, Dalton CH, Price ME, Graham SJ, Green AC, Jenner J, Groombridge HJ, Timperley CM (2015) Toxicity and medical countermeasure studies on the organophosphorus nerve agents VM and VX. Proc R Soc A Math Phys Eng Sci 471(2176):20140891. https:\/\/doi.org\/10.1098\/rspa.2014.0891","journal-title":"Proc R Soc A Math Phys Eng Sci"},{"key":"4355_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.tiv.2012.08.014","volume":"27","author":"P Rolland","year":"2013","unstructured":"Rolland P, Bolzinger MA, Cruz C, Josse D, Brian\u00e7on S (2013) Hairy skin exposure to VX in vitro: effectiveness of delayed decontamination. Toxicol in Vitro 27:358\u2013366. https:\/\/doi.org\/10.1016\/j.tiv.2012.08.014","journal-title":"Toxicol in Vitro"},{"key":"4355_CR58","doi-asserted-by":"publisher","first-page":"108150","DOI":"10.1016\/j.neuropharm.2020.108150","volume":"174","author":"Y Rosenberg","year":"2020","unstructured":"Rosenberg Y, Saxena A (2020) Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs. Neuropharmacology 174:108150. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108150","journal-title":"Neuropharmacology"},{"key":"4355_CR44","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2174\/138920112802273191","volume":"13","author":"MD Schwartz","year":"2012","unstructured":"Schwartz MD, Hurst CG, Kirk MA, Reedy SJD, Braue EH Jr (2012) Reactive skin decontamination lotion (RSDL) for the decontamination of chemical warfare agent (CWA) dermal exposure. Curr Pharm Biotechnol 13:1971\u20131979. https:\/\/doi.org\/10.2174\/138920112802273191","journal-title":"Curr Pharm Biotechnol"},{"key":"4355_CR45","unstructured":"Sim VM (1962) Variability of different intact human-skin sites to the penetration of VX. Technical Report CRDLR 3122. U.S. Army Chemical Corps Research and Development Command, Chemical Research and Development Laboratories, Army Medical Center, MD. https:\/\/apps.dtic.mil\/sti\/pdfs\/AD0271163.pdf"},{"key":"4355_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000029928","volume":"13","author":"GA Simon","year":"2000","unstructured":"Simon GA, Maibach HI (2000) The pig as an experimental animal model of percutaneous permeation in man: qualitative observations\u2014an overview. Skin Pharmacol Appl Skin Physiol 13:229\u2013234. https:\/\/doi.org\/10.1159\/000029928","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"4355_CR47","doi-asserted-by":"publisher","first-page":"14904","DOI":"10.1039\/d4ra02038c","volume":"14","author":"B Smolkin","year":"2024","unstructured":"Smolkin B, Nahum V, Bloch-Shilderman E, Nili U, Ashkenazi N (2024) Acetohydroxamic acid salts: mild, simple and effective degradation to counter \u201cNovichok\u201d nerve agents. RSC Adv 14:14904\u201314909. https:\/\/doi.org\/10.1039\/d4ra02038c","journal-title":"RSC Adv"},{"key":"4355_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(20)32644-1","volume":"397","author":"D Steindl","year":"2021","unstructured":"Steindl D, Boehmerle W, K\u00f6rner R, Praeger D, Haug M, Nee J, Schreiber A, Scheibe F, Demin K, Jacoby P, Tauber R, Hartwig S, Endres M, Eckardt KU (2021) Novichok nerve agent poisoning. Lancet 397:249\u2013252. https:\/\/doi.org\/10.1016\/S0140-6736(20)32644-1","journal-title":"Lancet"},{"key":"4355_CR49","doi-asserted-by":"publisher","unstructured":"Thiermann H, Aurbek N, Worek F (2016) Treatment of Nerve Agent Poisoning. In: Worek F, Jenner J, Thiermann H (eds) Chemical warfare toxicology, volume 2: management of poisoning. Royal Society of Toxicology, pp 1\u201342. https:\/\/doi.org\/10.1039\/9781782628071","DOI":"10.1039\/9781782628071"},{"key":"4355_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.toxlet.2017.02.001","volume":"269","author":"L Thors","year":"2017","unstructured":"Thors L, Lindberg S, Johansson S, Koch B, Koch M, H\u00e4gglund L, Bucht A (2017) RSDL decontamination of human skin contaminated with the nerve agent VX. Toxicol Lett 269:47\u201354. https:\/\/doi.org\/10.1016\/j.toxlet.2017.02.001","journal-title":"Toxicol Lett"},{"key":"4355_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/15569527.2021.1902342","volume":"40","author":"L Thors","year":"2021","unstructured":"Thors L, Wigenstam E, Qvarnstr\u00f6m J, Bucht A (2021) Efficient agent degradation within skin is important for decontamination of percutaneously exposed VX. Cutan Ocul Toxicol 40:95\u2013102. https:\/\/doi.org\/10.1080\/15569527.2021.1902342","journal-title":"Cutan Ocul Toxicol"},{"key":"4355_CR52","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/15563650.2018.1469759","volume":"56","author":"JA Vale","year":"2018","unstructured":"Vale JA, Marrs TC, Maynard RL (2018) Novichok: a murderous nerve agent attack in the UK. Clin Toxicol (Phila) 56:1093\u20131097. https:\/\/doi.org\/10.1080\/15563650.2018.1469759","journal-title":"Clin Toxicol (Phila)"},{"key":"4355_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/s0041-008x(03)00216-3","volume":"191","author":"MJ van der Schans","year":"2003","unstructured":"van der Schans MJ, Lander BJ, van der Wiel H, Langenberg JP, Benschop HP (2003) Toxicokinetics of the nerve agent (+\/-)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol 191:48\u201362. https:\/\/doi.org\/10.1016\/s0041-008x(03)00216-3","journal-title":"Toxicol Appl Pharmacol"},{"key":"4355_CR54","first-page":"109","volume-title":"Chemical warfare agents: chemistry, pharmacology, toxicology, and therapeutics","author":"MJ van der Schans","year":"2008","unstructured":"van der Schans MJ, Benschop HP, Whalley CE (2008) Toxicokinetics of nerve agents. In: Romano JA Jr, Lukey BJ, Salem H (eds) Chemical warfare agents: chemistry, pharmacology, toxicology, and therapeutics, 2nd edn. CRC Press Inc., Boca Raton, pp 109\u2013111","edition":"2"},{"key":"4355_CR55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/15376510701884944","volume":"18","author":"JR Wetherell","year":"2008","unstructured":"Wetherell JR, Armstrong SJ, Read RW, Clough GF (2008) VX penetration following percutaneous poisoning: a dermal microdialysis study in the guinea pig. Toxicol Mech Methods 18:313\u2013321. https:\/\/doi.org\/10.1080\/15376510701884944","journal-title":"Toxicol Mech Methods"},{"key":"4355_CR56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s002040050495","volume":"72","author":"F Worek","year":"1998","unstructured":"Worek F, Widmann R, Knopff O, Szinicz L (1998) Reactivating potency of obidoxime, pralidoxime, HI 6 and HLo 7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol 72:237\u2013243. https:\/\/doi.org\/10.1007\/s002040050495","journal-title":"Arch Toxicol"},{"key":"4355_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.toxlet.2010.10.009","volume":"200","author":"F Worek","year":"2011","unstructured":"Worek F, Aurbek N, Willea T, Eyer P, Thiermann H (2011) Kinetic analysis of interactions of paraoxon and oximes with human, Rhesus monkey, swine, rabbit, rat and guinea pig acetylcholinesterase. Toxicol Lett 200:19\u201323. https:\/\/doi.org\/10.1016\/j.toxlet.2010.10.009","journal-title":"Toxicol Lett"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04355-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04355-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04355-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:19:48Z","timestamp":1782512388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-026-04355-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4355"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04355-6","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest. The views expressed in this article are those of the authors and do not reflect the official policy of the IIBR (Israel Institute for Biological Research).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The experimental procedures were approved by the Institutional Animal Care and Use Committee at the IIBR (Protocols No. P-05-19, P-07-20 and P-05-22), and are in strict accordance with the Guide for the Care and Use of Laboratory Animals, The National Academies Press, Washington DC, 2011. The study was designed to prevent any unnecessary animal discomfort. A humane end point for euthanasia was defined as lack of approach to food and\/or water for\u2009>\u200924\u00a0h.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}